A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

NCT03674177 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

502

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: GSK3888550A RSV Maternal vaccine formulation 1
BIOLOGICAL: GSK3888550A RSV Maternal vaccine formulation 2
BIOLOGICAL: GSK3888550A RSV Maternal vaccine formulation 3
DRUG: Placebo (Normal Saline)

Sponsor

GlaxoSmithKline